Mr A. Malik is building a stake, now over 6.25%. A position on the Board or a takeover perhaps? FDBK is suffering under the pension fund deficit contingency, but with stock markets rising, the fund position may be improving. Sciences in the post secondary school seeing improvement and extra funding and promotion. All in all looks like an improving situation here.

It's a nice company, but I wonder if it should be "listed"? - if things get much worse, that will be dark day for investors. Relying on a political punchbag (schools/education) is not a strong business-model IMHO. If it represented a third or less (of T/O), then it's a nice earner and should enable them to be at the cutting-edge of University research.
They should get into something with a rising-potential....such as energy, or saving energy etc.
I no-longer hold. The sp says it all.

EDIT (29Nov2010)-Apologies, it seems I'm still hold and went to their agm today - grief, many suits and precious little was said. Two shareholders spoke and nothing good IMHO. That a director has bought 450,000 (at 2p) says a lot - not a ripple on the sp.(DYOR). Yet, back in June 2007 it was 5p-ish and years before, near 50p.
Mindyou that Dir was alone and spent under �10k, so not significant in my view.
Any other comments, observations etc.
EDIT-(15Dec10)-down 9% to 1.5p mid. (someone sold only �9k5-worth)....Oh deary.
EDIT ( 1Dec2015)- Little sp change, but Co has now sold the "Instruments" and now has CT-scan software - whether they are strong enough to get customers willing to pay...remains to be seen.

Feedback plc announced the adoption of its TexRAD research software by four leading cancer research institutions, in addition to a new research agreement.

More at http://tinyurl.com/mos5ftj

First sale of Texrad in South Korea.

Top performer today.

Has move forward after recent results and a video today explaining some of their business

youtube video FBDK

Cheap @2.75p my target is 10p.

Break-out this am..?

Moving the last couple of sessions.

Break out today.?

RNS out re strategy.

Feedback receives raft of new orders from university hospitals across Europe